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Human cells express only a small subset of their genome. Gene
expression is controlled by covalent modifications of the DNA
and the histone proteins, including methylation of histones’ lysine
residues. Rathert et al. studied the specificity of histone methyl-
transferases using peptide SPOT arrays as substrates. This ap-
proach allowed simultaneous investigation of enzyme activity on
400 different substrate peptides. For the Dim-5 histone-3 lysine-9
methyltransferase from Neurospora crassa, authors show recog-
nition of R8-G12 of the H3 tail, in excellent agreement with the
structure of Dim-5 in complex with a target peptide. Further-
more, they demonstrate that the specificity of histone methyl-
transferases can be altered by protein design. (Figure credits:
Rathert et al.).
A Revised Pathway for Wall Teichoic Acids Biosynthesis
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Cell walls of many Gram-positive bacteria are extensively decorated by anionic polymers known as wall teichoic acids (WTAs). WTAs
consist of a disaccharide-based linkage unit and a repeating polyol-phosphate polymer, synthesized in the cytoplasm and
translocated to the outside of the cell. Since WTAs are indispensable for Staphylococcus aureus colonization and infection, their
biosynthesis pathway represents a viable target for antibiotic development. To clarify the biosynthesis process for WTAs, Brown
et al. performed the in vitro reconstitution of the intracellular steps of poly-ribitol phosphate WTAs biosynthesis in S. aureus
NCTC8325. The authors assigned the function of each gene product involved in the process, which led to two significant revisions
of the previously proposed biosynthetic pathway.
Microbisporicin: A Different Inhibitor of Peptidoglycan Synthesis
PAGE 22
Antibiotics blocking bacterial cell wall assembly (b-lactams and glycopeptides) are
facing a challenge from the progressive spread of resistant pathogens. Lantibiotics
are promising candidates to alleviate this problem. Microbisporicin, a lantibiotic
produced by an uncommon actinomycete and discovered in the course of a biolog-
ical activity-guided screening, is a potent antibacterial. Castiglione et al. show that
it is produced as two structurally related and similarly active 24-mer peptides, con-
taining two novel posttranslational modifications and five thioether intramolecular
bridges. Its spectrum of activity covers most of the Gram-positives and some
Gram-negatives ofmedical importance. Considering also its efficacy in vivo,micro-
bisporicin represents a new antibiotic to treat emerging infections. (Figure credits:
Castiglione et al.)
Reprogramming Genetic Code for N-methyl-peptide Synthesis
PAGE 32
N-methyl amino acids are often contained in naturally occurring peptide products and confer proteolytic stability and membrane-
permeability upon them. Kawakami et al. report a new approach for the programmed synthesis of N-methyl-peptides using an
E. coli reconstituted translation system. The key technology in this study is a ribozyme-basedde novo tRNAacylation, called flexizyme,
system that enables reprogramming of the genetic code. The authors demonstrate messenger RNA-directed synthesis of linear and
cyclic N-methyl-peptides. This technology offers a tool for the construction of diverse N-methyl-peptide libraries, potentially leading to
the discovery of in vivo compatible therapeutic peptides.Chemistry & Biology 15, January 2008 ª2008 Elsevier Ltd All rights reserved ix
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Nitric oxide (NO) is an important signaling molecule in eukaryotic metabolism and pathogen defense. In mammals, NO is produced
by nitric oxide synthases (NOSs). Genome sequencing identified truncated mammalian NOS homologs in multiple Gram-positive
bacteria. The study by Johnson et al. provides the first direct evidence of in vivo NO production by bacterial NOS-like proteins in
plant-pathogenicStreptomyces species. This NO is produced in response to host-derived signals and at the host pathogen interface,
suggesting a possible role inmanipulating host signaling. Since some of the human pathogens also contain NOS, the authors suggest
that NOS-produced NO might be important for the host-pathogen interactions across kingdoms.
Targeting Phenolic Glycolipids Biosynthesis to Treat Mycobacterial
Infections
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Phenolic glycolipids (PGLs) are polyketide-derived small-molecule virulence factors
produced by mycobacterial pathogens. Ferreras et al. combined bioinformatic,
genetic, biochemical, and chemical biology approaches to illuminate the mecha-
nism of chain initiation required for assembly of the phenolphthiocerol moiety of
PGLs. The insights gained allowed the authors to develop a PGL assembly inhibitor
with potent activity in several mycobacterial pathogens. This work advances our
understanding of the biosynthesis of an important group of mycobacterial virulence
effectors and provides support for the feasibility of targeting PGL biosynthesis to
develop new drugs to treat mycobacterial infections. (Figure credits: Ferreras
et al.; artistic rendition of PGL structure.)
Rescue of F508del-CFTR by Solubilizing Mutations
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The most frequent pathogenic mutation in Cystic Fibrosis (CF) is F508del, found in the first nucleotide-binding domain (NBD1) of CF
transmembrane conductance regulator (CFTR) protein. F508del mutation disrupts biosynthesis, cell surface expression, and channel
gating of CFTR, thus resulting in severe disease phenotype. The current high-resolution structure of F508del NBD1 domain of CFTR
was determined upon introduction of a number of additional mutations to improve protein solubility. Here, Pissarra et al. investigate
the effect of these additional mutations and demonstrate that these solubilizing mutations attenuate both the trafficking and
functional defects of F508del-CFTR in vivo, thus suggesting that the existing structure of F508del-NBD1 corresponds to a partially
corrected conformation. Accordingly, the structure of F508del-NBD1 without additional mutations is still needed to understand how
F508del impacts on NBD1 conformation.
Exploiting Evolutionary Divergence of Parasite and Host Enzymes
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The ‘‘vicious cycle of diarrhea and malnutrition’’ in
developing countries could be broken with effective
chemotherapy against Cryptosporidium. This proto-
zoan parasite also poses a credible bioterrorism threat.
Eukaryotic pathogens present a particularly challeng-
ingproblem fordrugdesignbecause the targets resem-
ble host proteins. Surprisingly, the purine salvage path-
way of Cryptosporiium relies on an enzyme obtained
from a prokaryote via horizontal gene transfer, which
is very different from the host counterpart. Umejiego
et al. designed an HTS to target the most diverged
binding site. This screen identified parasite-selective
inhibitors that are more effective than paromomycin,
the current standard for anticryptosporidial activity.
(Figure adapted from Umejiego et al.)
Engineered Biosynthesis of Oxo-Amphotericins
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Amphotericin B is an effective but toxic antifungal antibiotic that is produced by Streptomyces nodosus. In addition, the compound is
also active against enveloped viruses, protozoan parasites, and pathogenic prion proteins. Therefore, there is considerable interest in
production of nontoxic analogs by both chemical modification and by genetic manipulation of S. nodosus. Here, Power et al. report
engineering of amphotericin biosynthetic genes to introduce ketone groups at different positions of the macrolactone core. This
approach provides starting material for a range of interesting semisynthetic derivatives, with optimized therapeutic properties.Chemistry & Biology 15, January 2008 ª2008 Elsevier Ltd All rights reserved xi
